Acute asthma attack. Severe persistent asthma
Conditions
Interventions
Intervention 1: Case group: Children aged 13-5 years will receive 5 mg of oral memontelocut as a single dose in addition to standard primary treatment. Intervention 2: Control group:2. The control gro
Sponsors
Ghoum University of Medical Sciences
Eligibility
Sex/Gender
All
Age
5 Years to 13 Years
Inclusion criteria
Inclusion criteria: Children aged 5-13 years Children with an acute asthma attack
Exclusion criteria
Exclusion criteria: Parents' lack of consent to participate in the study The child's heart, lung, and metabolic diseases Children under 5 years old and over 13 years old History of anti-leukotriene use in the last two weeks Children who need intubation for treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PEF. Timepoint: PEF measurement on arrival and 6 hours later. Method of measurement: Picoflowmeter device.;The effect of adding oral montelukast to standard treatment on patient's blood oxygen. Timepoint: Upon arrival and 6 hours later. Method of measurement: with pulse oximeter. | — |
Secondary
| Measure | Time frame |
|---|---|
| Effect of adding oral montelukast to standard treatment on vital signs. Timepoint: Upon arrival and 6 hours later. Method of measurement: Examination of the patient by a doctor.;Effect of adding oral montelukast to standard treatment on respiratory distress. Timepoint: Upon arrival and 6 hours later. Method of measurement: Examination of the patient by a doctor. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyed Salman Moosavinejad
Ghoum University of Medical Sciences
Outcome results
None listed